J. Goldman & CO LP Biogen Inc. Transaction History

J. Goldman & CO LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$253.3 - $285.89 $14.4 Million - $16.3 Million	56,921 New	56,921 $14.6 Million
Q1 2023 May 15, 2023	BUY	$256.56 - $292.34 $7.29 Million - $8.31 Million	28,426 Added 232.81%	40,636 $11.3 Million
Q4 2022 Feb 14, 2023	BUY	$252.44 - $306.72 $1.04 Million - $1.27 Million	4,131 Added 51.13%	12,210 $3.38 Million
Q3 2022 Nov 14, 2022	SELL	$194.69 - $268.46 $1.7 Million - $2.35 Million	-8,736 Reduced 51.95%	8,079 $2.16 Million
Q2 2022 Aug 15, 2022	BUY	$187.54 - $223.02 $3.15 Million - $3.75 Million	16,815 New	16,815 $3.43 Million
Q1 2021 May 17, 2021	SELL	$242.95 - $284.63 $888,468 - $1.04 Million	-3,657 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$236.26 - $355.63 $864,002 - $1.3 Million	3,657 New	3,657 $895,000

1,037

126M

1.13M

1.43M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $21.5B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of J. Goldman & CO LP, based on Form 13F filings with the SEC.

Stay updated on J. Goldman & CO LP with notifications on news.